Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Main Capital and Alfa eCare in connection with their strategic acquisition of Joliv
Mandate

Vinge has advised Main Capital and Alfa eCare in connection with their strategic acquisition of Joliv

June 16, 2020 Employment and Benefits Banking and Finance Intellectual Property M&A IT, Telecommunications and Outsourcing

The Alfa eCare group is a recognized eHealth software company, providing solutions to both public and private healthcare providers throughout Sweden.

Joliv provides a range of eHealth solutions servicing over 120 clients primarily in the elderly care market. Joliv’s solutions contribute to a safe and quality-assured work environment for care providers with reduced administration needs and more time for personal meetings with patients. The strategic merge creates a one-stop-shop offering for the Swedish care market helping care providers and municipalities to further improve the quality of care provision.
 
Vinge’s team consisted of Filip Öhrner, Kristina Ekberg, Jesper Lindvall, Jonathan Riddersholm, Ellen Åkerdahl Flygt (M&A), Ebba Svenburg (Employment), Karl-Hugo Engdahl (Agreements and GDPR/IT), Stojan Arnerstål (IPR), Mikael Ståhl, Axel Jansson (Banking and Finance), Carl Bruneheim and Nathalie Hughes (VDR Assistants).

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026